Congress trades
Editas Medicine, Inc. (EDIT)
About Editas Medicine, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Gilmore O'Neill
- Employees
- 87
- Listed since
- Feb 3, 2016
- Market value
- $425.1M
- Price to earnings
- -
- Earnings per share
- -$0.62
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 9, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | -$0.15 | -$0.27 | $11.9M | $2.8M | EPS beatRevenue beat |
| Q1 FY2026reported May 5, 2026 | -$0.26 | -$0.30 | $2.8M | $6.4M | EPS beatRevenue miss |
| Q4 FY2025reported Mar 9, 2026 | -$0.06 | -$0.27 | $24.7M | $8.3M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 10, 2025 | -$0.28 | -$0.38 | $7.5M | $8.5M | EPS beatRevenue miss |
| Q2 FY2025reported Aug 12, 2025 | -$0.63 | -$0.41 | $3.6M | $1.8M | EPS missRevenue beat |
| Q1 FY2025reported May 12, 2025 | -$0.92 | -$0.56 | $4.7M | $642K | EPS missRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Gilmore O’Neill, M.B., M.M.Sc.President and Chief Executive Officer | $687K | $0 | $1.7M | $2.4M |
| Linda C. Burkly, Ph.D.Executive Vice President and Chief Scientific Officer | $517K | $0 | $659K | $1.2M |
| Amy ParisonSenior Vice President and Chief Financial Officer | $394K | $0 | $427K | $822K |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.0M | 11,111,111 | +100.0% | 9.31% |
| Blackrock, Inc. | $34.3M | 10,589,990 | +14.3% | 8.88% |
| RA Capital Management, L.P. | $28.8M | 8,889,000 | +100.0% | 7.45% |
| Commodore Capital LP | $28.8M | 8,889,000 | +100.0% | 7.45% |
| Adar1 Capital Management, LLC | $28.8M | 8,889,000 | +100.0% | 7.45% |
| Vanguard Capital Management LLC | $19.9M | 6,141,336 | +46.1% | 5.15% |
| Paradigm Biocapital Advisors LP | $18.1M | 5,586,625 | +100.0% | 4.68% |
| Opaleye Management Inc. | $12.5M | 3,861,930 | +100.4% | 3.24% |
| Vanguard Portfolio Management LLC | $11.7M | 3,598,339 | +14.3% | 3.02% |
| Woodline Partners LP | $11.5M | 3,555,497 | +100.0% | 2.98% |
| VIVO Capital, LLC | $11.5M | 3,555,250 | +100.0% | 2.98% |
| Gordonmd Global Investments LP | $10.1M | 3,127,000 | +100.0% | 2.62% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in EDIT
12 disclosures of 12 on record · median 25d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | -58.2%S&P +86.2% · vs S&P 500 -144.4% | Apr 10, 2023 | May 19, 2023 | 39d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -93.3%S&P +85.3% · vs S&P 500 -178.6% | Apr 14, 2021 | May 1, 2021 | 17d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -93.9%S&P +97.2% · vs S&P 500 -191.2% | Mar 2, 2021 | Apr 1, 2021 | 30d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -90.4%S&P +111.5% · vs S&P 500 -201.9% | Nov 17, 2020 | Dec 1, 2020 | 14d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -87.5%S&P +169.8% · vs S&P 500 -257.3% | May 1, 2020 | May 31, 2020 | 30d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -89.1%S&P +165.6% · vs S&P 500 -254.7% | Apr 27, 2020 | May 9, 2020 | 12d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -90.1%S&P +135.8% · vs S&P 500 -225.9% | Jan 27, 2020 | Feb 22, 2020 | 26d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -91.0%S&P +133.5% · vs S&P 500 -224.5% | Jan 9, 2020 | Feb 22, 2020 | 44d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -91.4%S&P +137.5% · vs S&P 500 -228.9% | Dec 23, 2019 | Jan 2, 2020 | 10d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -88.9%S&P +144.7% · vs S&P 500 -233.6% | Nov 19, 2019 | Dec 14, 2019 | 25d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -88.6%S&P +145.4% · vs S&P 500 -234.0% | Nov 22, 2019 | Dec 14, 2019 | 22d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -90.9%S&P +143.1% · vs S&P 500 -234.0% | Dec 9, 2019 | Dec 14, 2019 | 5d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded EDIT?
Daniel S. Goldman, Donald S. Beyer, Jr. disclosed EDIT transactions in the filings shown here.
How quickly are EDIT trades disclosed?
Congressional disclosures took a median of 25 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.